Claudin-6-specific immunoreceptors and T cell epitopes

Patent metadata

Field	Value
Publication number	US-10370423-B2
Application number	US-201515124640-A
Country	US
Kind code	B2
Filing date	Mar 30, 2015
Priority date	Apr 1, 2014
Publication date	Aug 6, 2019
Grant date	Aug 6, 2019

Abstract

The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.

First claim

The invention claimed is:

1. A method of treating a cancer disease comprising administering a pharmaceutical composition to a patient having claudin-6 (CLDN6)-expressing cancer cells, the pharmaceutical composition comprising a nucleic acid having a nucleic acid sequence encoding an artificial T cell receptor which specifically binds CLDN6 and comprises an amino acid sequence at least 95% identical to SEQ ID NO: 46, wherein the binding domain for CLDN6 comprises the complementarity-determining regions CDR1, CDR2, and CDR3 of the heavy chain variable region according to SEQ ID NO: 32 and the complementarity-determining regions CDR1, CDR2, and CDR3 of the light chain variable region according to SEQ ID NO: 39.

2. A method for inducing an immune response in a subject having claudin-6 (CLDN6)-expressing cancer cells, the method comprising administering to the subject a pharmaceutical composition comprising a nucleic acid having a nucleic acid sequence encoding an artificial T cell receptor which specifically binds CLDN6 and comprises an amino acid sequence at least 95% identical to SEQ ID NO: 46, wherein the binding domain for CLDN6 comprises the complementarity-determining regions CDR1, CDR2, and CDR3 of the heavy chain variable region according to SEQ ID NO: 32 and the complementarity-determining regions CDR1, CDR2, and CDR3 of the light chain variable region according to SEQ ID NO: 39.

3. A method of killing cancer cells in a subject having CLDN6-expressing cancer cells, comprising the step of providing to the subject a therapeutically effective amount of a nucleic acid having a nucleic acid sequence encoding an artificial T cell receptor which specifically binds CLDN6 and comprises an amino acid sequence at least 95% identical to SEQ ID NO: 46, wherein the binding domain for CLDN6 comprises the complementarity-determining regions CDR1, CDR2, and CDR3 of the heavy chain variable region according to SEQ ID NO: 32 and the complementarity-determining regions CDR1, CDR2, and CDR3 of the light chain variable region according to SEQ ID NO: 39.

4. A method of killing cancer cells in a subject having CLDN6-expressing cancer cells, comprising the step of providing to the subject a therapeutically effective amount of a cell comprising a nucleic acid having a nucleic acid sequence encoding an artificial T cell receptor which specifically binds CLDN6 and comprises an amino acid sequence at least 95% identical to SEQ ID NO: 46, wherein the binding domain for CLDN6 comprises the complementarity-determining regions CDR1, CDR2, and CDR3 of the heavy chain variable region according to SEQ ID NO: 32 and the complementarity-determining regions CDR1, CDR2, and CDR3 of the light chain variable region according to SEQ ID NO: 39.

5. A method of killing cancer cells in a subject having CLDN6-expressing cancer cells, comprising the step of providing to the subject a therapeutically effective amount of an immunoreactive cell obtainable from a method comprising the step of transducing a T cell with a nucleic acid having a nucleic acid sequence encoding an artificial T cell receptor which specifically binds CLDN6 and comprises an amino acid sequence at least 95% identical to SEQ ID NO: 46, wherein the binding domain for CLDN6 comprises the complementarity-determining regions CDR1, CDR2, and CDR3 of the heavy chain variable region according to SEQ ID NO: 32 and the complementarity-determining regions CDR1, CDR2, and CDR3 of the light chain variable region according to SEQ ID NO: 39.

6. A method of killing cancer cells in a subject having CLDN6-expressing cancer cells, comprising the step of providing to the subject a therapeutically effective amount of an artificial T cell receptor which specifically binds CLDN6 and comprises an amino acid sequence at least 95% identical to SEQ ID NO: 46, wherein the binding domain for CLDN6 comprises the complementarity-determining regions CDR1, CDR2, and CDR3 of the heavy chain variable region according to SEQ ID NO: 32 and the complementarity-determining regions CDR1, CDR2, and CDR3 of the light chain variable region according to SEQ ID NO: 39.

7. The method of claim 1 , 2 , 3 , 4 , 5 or 6 , wherein the artificial T cell receptor comprises a binding domain, said binding domain comprises a heavy chain variable region (VH) and a light chain variable region (VL), and wherein the VH comprises an amino acid sequence of SEQ ID NO: 32 and the VL comprises an amino acid sequence of SEQ ID NO: 39.

8. The method of claim 1 , 2 , 3 , 4 , 5 or 6 , wherein the artificial T cell receptor comprises an amino acid sequence of SEQ ID NO: 46.

Assignees

• Biontech Cell & Gene Therapies Gmbh
• Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
• Univ Der Johannes Gutenberg Univ Mainz
• Ganymed Pharmaceuticals Ag
• Biotech Cell & Gene thrapies GMBH
• Tron—Translationale Onkologie Ander Univ Tsmedizin Der Johannes Gutenberg Univ Main
• Ganymed Pharmceuticals AG

Inventors

• Sahin Ugur
• Türeci Özlem
• Simon Petra
• Omokoko Tana
• Hoff Holger
• Voss Ralf-Holger
• Breitkreuz Andrea
• Hobohm Kathleen
• Mroz Karolina Anna

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• G01N33/575

  for cancer · CPC title

• C07K14/7051

  T-cell receptor (TcR)-CD3 complex · CPC title

• G01N33/505

  involving T-cells · CPC title